NASDAQ: GYRE - Gyre Therapeutics, Inc.

Yield per half year: -10.06%
Dividend yield: 0%

Share chart Gyre Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.

more details
The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2006-04-12
ISIN US4037831033
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 25.05
Сайт https://www.gyretx.com
Цена ао 11.5
Change price per day: +3.75% (10.94)
Change price per week: +19.1% (9.53)
Change price per month: +42.95% (7.94)
Change price per 3 month: -5.26% (11.98)
Change price per half year: -10.06% (12.62)
Change price per year: -20.29% (14.24)
Change price per 3 year: +1 433.78% (0.74)
Change price per 5 year: +13.96% (9.96)
Change price per year to date: +1.89% (11.14)
All parameters

Underestimation

Title Value Grade
P/S 12.25 1
P/BV 13.16 1
P/E 107.16 1
EV/EBITDA 79.49 1
Total: 1.88

Efficiency

Title Value Grade
ROA, % 9.99 3
ROE, % 50.89 10
Total: 5.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.5 5
Total: 2.22

Debt

Title Value Grade
Debt/EBITDA 0.0989 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 3204.91 10
Yield Ebitda, % -283.67 0
Yield EPS, % -126.61 0
Total: 2
More

Institutions Volume Share, %
Renaissance Technologies, LLC 39379 0.1
Geode Capital Management, LLC 17250 0.05
Vanguard Group Inc 13793 0.04
Blackrock Inc. 10250 0.03
Citigroup Inc. 7748 0.02
Morgan Stanley 6516 0.02
Kynam Capital Management, LP 6004 0.02
Northern Trust Corporation 5761 0.02
State Street Corporation 4840 0.01
Nantahala Capital Management, LLC 4520 0.01

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Morningstar Small-Cap Value ETF 0.00477 187.77 2.50476
iShares Morningstar Small-Cap ETF 0.00416 391.25 1.60498
iShares Morningstar Small-Cap Growth ETF 0.00411 595.05 0.72598
0391.361.61

Head Job title Payment Year of birth
Dr. Han Ying Ph.D. CEO & Director 10.5k 1966 (59 years)
Mr. Songjiang Ma President & Director N/A 1956 (69 years)
Ms. Ruoyu Chen Chief Financial Officer 121.35k 1971 (54 years)
Mr. Weiguo Ye Chief Operating Officer 274.62k 1978 (47 years)
Ms. Seline E. Miller CPA Senior Vice President of Finance N/A 1970 (55 years)

Address: United States, San Diego. CA, 12770 High Bluff Drive - open in Google maps, open in Yandex maps
Website: https://www.gyretx.com